ESMO and WHO: 14 years of working in partnership on cancer control.
作者信息
Ullrich Andreas, Ciardiello Fortunato, Bricalli Gracemarie, Cherny Nathan I, Eniu Alexandru
机构信息
World Health Organization , Geneva , Switzerland.
Second University of Naples , Naples , Italy.
出版信息
ESMO Open. 2016 May 26;1(3):e000012. doi: 10.1136/esmoopen-2015-000012. eCollection 2016.
Abstract
摘要
相似文献
1
ESMO and WHO: 14 years of working in partnership on cancer control.
ESMO Open. 2016 May 26;1(3):e000012. doi: 10.1136/esmoopen-2015-000012. eCollection 2016.
2
Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting.
J Manag Care Spec Pharm. 2017 Jun;23(6-a Suppl):S34-S48. doi: 10.18553/jmcp.2017.23.6-a.s34.
3
ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers.
ESMO Open. 2016 Oct 18;1(5):e000100. doi: 10.1136/esmoopen-2016-000100. eCollection 2016.
4
ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0).
Ann Oncol. 2025 May 21. doi: 10.1016/j.annonc.2025.04.006.
5
ESMO-Magnitude of Clinical Benefit Scale version 1.1.
Ann Oncol. 2017 Oct 1;28(10):2340-2366. doi: 10.1093/annonc/mdx310.
6
The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna.
ESMO Open. 2017 Jul 16;2(3):e000166. doi: 10.1136/esmoopen-2017-000166. eCollection 2017.
7
Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1.
ESMO Open. 2020 Sep;5(5):e000681. doi: 10.1136/esmoopen-2020-000681.
8
The European Society for Medical Oncology (ESMO) Precision Medicine Glossary.
Ann Oncol. 2018 Jan 1;29(1):30-35. doi: 10.1093/annonc/mdx707.
9
The ESMO-Magnitude of Clinical Benefit Scale for novel oncology drugs: correspondence with three years of reimbursement decisions in Israel.
Expert Rev Pharmacoecon Outcomes Res. 2018 Feb;18(1):119-122. doi: 10.1080/14737167.2017.1343146. Epub 2017 Jun 21.
10
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.
Ann Oncol. 2020 Feb;31(2):191-201. doi: 10.1016/j.annonc.2019.10.026. Epub 2019 Dec 20.
引用本文的文献
1
WHO-ESMO collaboration in cancer control: policies into action to save lives.
ESMO Open. 2022 Feb;7(1):100373. doi: 10.1016/j.esmoop.2021.100373. Epub 2022 Jan 31.
2
Cancer medicines in Asia and Asia-Pacific: What is available, and is it effective enough?
ESMO Open. 2019 Jul 17;4(4):e000483. doi: 10.1136/esmoopen-2018-000483. eCollection 2019.
3
Global cancer control: responding to the growing burden, rising costs and inequalities in access.
ESMO Open. 2018 Feb 2;3(2):e000285. doi: 10.1136/esmoopen-2017-000285. eCollection 2018.
4
ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe.
Ann Oncol. 2017 Nov 1;28(11):2633-2647. doi: 10.1093/annonc/mdx521.
本文引用的文献
1
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).
Ann Oncol. 2015 Aug;26(8):1547-73. doi: 10.1093/annonc/mdv249. Epub 2015 May 30.
2
Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2).
Lancet. 2015 Mar 14;385(9972):977-1010. doi: 10.1016/S0140-6736(14)62038-9. Epub 2014 Nov 26.
3
The Global Opioid Policy Initiative (GOPI) project to evaluate the availability and accessibility of opioids for the management of cancer pain in Africa, Asia, Latin America and the Caribbean, and the Middle East: introduction and methodology.
Ann Oncol. 2013 Dec;24 Suppl 11:xi7-13. doi: 10.1093/annonc/mdt498.
4
Cancer in Africa: supporting advocates to stop the runaway train.
Ann Oncol. 2013 Apr;24(4):855-6. doi: 10.1093/annonc/mdt062.
5
Chronic non-communicable diseases, the European Chronic Disease Alliance--and cancer.
Ann Oncol. 2011 Feb;22(2):248-9. doi: 10.1093/annonc/mdq753.
6
Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: a report from the ESMO/EAPC Opioid Policy Initiative.
Ann Oncol. 2010 Mar;21(3):615-626. doi: 10.1093/annonc/mdp581.
7
The perspective and role of the medical oncologist in cancer prevention: a position paper by the European Society for Medical Oncology.
Ann Oncol. 2008 Jun;19(6):1033-5. doi: 10.1093/annonc/mdn366.
8
Recommendations for a Global Core Curriculum in Medical Oncology.
Ann Oncol. 2004 Nov;15(11):1603-12. doi: 10.1093/annonc/mdh447.
Zotero 插件